Harrow (HROW) Deferred Taxes (2017 - 2024)

Harrow's (HROW) quarterly Deferred Taxes came in at $20000.0 in Q3 2024, up 106.94% quarter-over-quarter from -$288000.0 in Q1 2023.

Harrow (HROW) Deferred Taxes (2017 - 2024) Analysis & Trends

Harrow's Deferred Taxes history runs 3 years deep, the most recent figure standing at $20000.0 for Q3 2024.

On a quarterly basis, Deferred Taxes changed N/A year-over-year to $20000.0 in Q3 2024; TTM through Sep 2024 was -$1.1 million, a N/A change from a year earlier, with the FY2018 full-year figure at $3.3 million, up 452.3% from the prior year.
Deferred Taxes rose to $20000.0 in Q3 2024 per HROW's latest filing, from -$288000.0 in the prior quarter.
Across five years, Deferred Taxes topped out at $20000.0 in Q3 2024 and bottomed at -$288000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-22.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	34.00 Mn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	25.90 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	-69.70 Mn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-61.10 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Harrow	1.56 Bn	1.47 Bn	27.05 Mn	-

Download Data